CO2017009404A2 - Inhibidores de calicreina plasmática y uso de los mismos para prevenir el ataque del angioedema hereditario - Google Patents
Inhibidores de calicreina plasmática y uso de los mismos para prevenir el ataque del angioedema hereditarioInfo
- Publication number
- CO2017009404A2 CO2017009404A2 CONC2017/0009404A CO2017009404A CO2017009404A2 CO 2017009404 A2 CO2017009404 A2 CO 2017009404A2 CO 2017009404 A CO2017009404 A CO 2017009404A CO 2017009404 A2 CO2017009404 A2 CO 2017009404A2
- Authority
- CO
- Colombia
- Prior art keywords
- hereditary angioedema
- attack
- prevent
- plasma kallikrein
- kallikrein inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562140289P | 2015-03-30 | 2015-03-30 | |
| US201562140277P | 2015-03-30 | 2015-03-30 | |
| US201562214293P | 2015-09-04 | 2015-09-04 | |
| PCT/US2016/024921 WO2016160926A1 (en) | 2015-03-30 | 2016-03-30 | Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017009404A2 true CO2017009404A2 (es) | 2018-03-09 |
Family
ID=57005262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0009404A CO2017009404A2 (es) | 2015-03-30 | 2017-09-15 | Inhibidores de calicreina plasmática y uso de los mismos para prevenir el ataque del angioedema hereditario |
Country Status (14)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3459564T1 (sl) | 2010-01-06 | 2022-06-30 | Takeda Pharmaceutical Company Limited | Proteini, ki vežejo plazemski kalikrein |
| JP2014506257A (ja) | 2011-01-06 | 2014-03-13 | ダイアックス コーポレーション | 血漿カリクレイン結合タンパク質 |
| CN111704672B (zh) | 2013-03-15 | 2024-06-04 | 武田药品工业株式会社 | 抗血浆激肽释放酶抗体 |
| EA038532B1 (ru) | 2014-01-21 | 2021-09-10 | Такеда Фармасьютикал Компани Лимитед | Способ лечения наследственного ангионевротического отека (hae) |
| IL295414B1 (en) | 2014-03-27 | 2025-10-01 | Takeda Pharmaceuticals Co | Compositions and methods for treating macular edema due to diabetes |
| US11286307B2 (en) * | 2015-12-11 | 2022-03-29 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| BR112019005167A2 (pt) * | 2016-09-16 | 2019-07-02 | Dyax Corp. | método e kit para analisar uma amostra |
| JP7210540B2 (ja) * | 2017-08-04 | 2023-01-23 | 武田薬品工業株式会社 | 血漿カリクレインの阻害剤およびその使用 |
| WO2019166572A1 (en) * | 2018-02-28 | 2019-09-06 | Pharming Intellectual Property B.V. | Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor |
| CA3092538A1 (en) * | 2018-02-28 | 2019-09-06 | Lifesci Pharmaceuticals, Inc. | Treatment of hereditary angioedema |
| MX2021002349A (es) * | 2018-08-30 | 2021-05-31 | Takeda Pharmaceuticals Co | Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario. |
| CN114166924B (zh) * | 2021-12-03 | 2024-11-22 | 中国医学科学院北京协和医院 | 尿液蛋白标志物在诊断遗传性血管水肿中的用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| ES2227545T3 (es) | 1994-01-11 | 2005-04-01 | Dyax Corporation | Proteinas y sus analogos del "dominio de kunitz" inhibidores de calicreina. |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| DE60333758D1 (de) | 2002-06-07 | 2010-09-23 | Dyax Corp | Prevention und Verringerung von Ischemia |
| US7132100B2 (en) * | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| SI3459564T1 (sl) * | 2010-01-06 | 2022-06-30 | Takeda Pharmaceutical Company Limited | Proteini, ki vežejo plazemski kalikrein |
| JP2014506257A (ja) * | 2011-01-06 | 2014-03-13 | ダイアックス コーポレーション | 血漿カリクレイン結合タンパク質 |
| WO2012151247A2 (en) * | 2011-05-02 | 2012-11-08 | Millennium Pharmaceuticals, Inc. | FORMULATION FOR ANTI-α4β7 ANTIBODY |
| US9216219B2 (en) * | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| EP3456744B1 (en) * | 2013-01-20 | 2023-03-29 | Takeda Pharmaceutical Company Limited | Evaluation and treatment of bradykinin-mediated disorders |
| CN111704672B (zh) * | 2013-03-15 | 2024-06-04 | 武田药品工业株式会社 | 抗血浆激肽释放酶抗体 |
| KR20140119396A (ko) * | 2013-03-29 | 2014-10-10 | 삼성전자주식회사 | 단백질 약물의 액상 제형 |
| AU2014340450B2 (en) * | 2013-10-21 | 2020-05-21 | Takeda Pharmaceutical Company Limited | Assays for determining plasma kallikrein system biomarkers |
| EA038532B1 (ru) * | 2014-01-21 | 2021-09-10 | Такеда Фармасьютикал Компани Лимитед | Способ лечения наследственного ангионевротического отека (hae) |
-
2016
- 2016-03-30 EP EP16774069.5A patent/EP3286226A4/en not_active Withdrawn
- 2016-03-30 WO PCT/US2016/024921 patent/WO2016160926A1/en not_active Ceased
- 2016-03-30 KR KR1020177031279A patent/KR102607829B1/ko active Active
- 2016-03-30 US US15/562,671 patent/US20180298110A1/en not_active Abandoned
- 2016-03-30 KR KR1020257012913A patent/KR20250057946A/ko active Pending
- 2016-03-30 HK HK18110329.1A patent/HK1250995A1/zh unknown
- 2016-03-30 JP JP2017549388A patent/JP7008920B2/ja active Active
- 2016-03-30 AU AU2016243160A patent/AU2016243160B2/en active Active
- 2016-03-30 CN CN201680018200.7A patent/CN107614532A/zh active Pending
- 2016-03-30 EA EA201792161A patent/EA201792161A1/ru unknown
- 2016-03-30 BR BR112017020864-4A patent/BR112017020864A2/en not_active Application Discontinuation
- 2016-03-30 IL IL305207A patent/IL305207A/en unknown
- 2016-03-30 IL IL254292A patent/IL254292B1/en unknown
- 2016-03-30 MX MX2017012423A patent/MX2017012423A/es unknown
- 2016-03-30 CA CA2979713A patent/CA2979713A1/en active Pending
- 2016-03-30 EP EP21167802.4A patent/EP3916020A1/en active Pending
- 2016-03-30 KR KR1020237040648A patent/KR102799778B1/ko active Active
-
2017
- 2017-09-15 CO CONC2017/0009404A patent/CO2017009404A2/es unknown
- 2017-09-27 MX MX2023010206A patent/MX2023010206A/es unknown
-
2021
- 2021-10-13 US US17/500,214 patent/US20220169749A1/en active Pending
- 2021-12-16 JP JP2021204200A patent/JP7309836B2/ja active Active
-
2022
- 2022-05-12 AU AU2022203180A patent/AU2022203180B2/en active Active
-
2023
- 2023-07-05 JP JP2023110592A patent/JP2023130442A/ja active Pending
-
2025
- 2025-11-21 AU AU2025271115A patent/AU2025271115A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017009404A2 (es) | Inhibidores de calicreina plasmática y uso de los mismos para prevenir el ataque del angioedema hereditario | |
| CL2016001231A1 (es) | Compuestos de inhibidor de autotaxina | |
| CL2018001134A1 (es) | Composiciones y métodos para inhibir la actividad arginasa | |
| UY37381A (es) | Compuestos que inhiben proteasas 3c y 3cl y métodos de uso de los mismos | |
| CL2015002472A1 (es) | Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4. | |
| CL2015001377A1 (es) | Inhbibidores de bmi-1 primidinas sustituidas inversas | |
| EP4193993A3 (en) | Combinations of cannabinoids and n-acylethanolamines | |
| CL2015002151A1 (es) | Biaril amide compuestos como inhibidores de quinasa | |
| BR112017006664A2 (pt) | terapias de combinação | |
| MX378273B (es) | Compuestos activos hacia bromodominios. | |
| CL2018001226A1 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
| MX2017006653A (es) | Metodos para modular los niveles de fármaco en plasma mediante el uso de eritrohidroxibupropión. | |
| BR112015011756A2 (pt) | inibidores da glutamase e métodos de uso | |
| SV2017005489A (es) | Terapias de combinación para el tratamiento de cánceres | |
| TR201819092T4 (tr) | Serin proteaz inhibitörleri olarak multi-sübstüte edilmiş aromatik bileşikler. | |
| IL259691A (en) | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack | |
| MX373965B (es) | Composiciones de inhibidores de c1 esterasa para usarse en el tratamiento, inhibición, o prevención de angioedema hereditario (hae). | |
| MX2022007436A (es) | Inhibidores de la autotaxina y sus usos. | |
| CL2015002897A1 (es) | Inhibidores de bace1 | |
| CL2016002151A1 (es) | Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico | |
| MX374385B (es) | Apilimod para uso en el tratamiento de melanoma. | |
| DOP2018000066A (es) | Compuestos útiles para inhibir ror-gamma-t | |
| PH12017501022B1 (en) | Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same | |
| EA201890212A1 (ru) | Новое применение сульфата декстрана | |
| UY36217A (es) | Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso. |